While relinquishing the 3.5mL platform, the company confirmed it will retain full development and manufacturing responsibilities for other versions of the system, including the larger 10mL on-body delivery device. This move allows the manufacturer to streamline its focus on its core injectable solutions business.

West, which operates 26 manufacturing sites globally and employs over 10,000 people, reported $3.07 billion in net sales for the 2025 fiscal year. The company remains a significant player in the sector, supplying more than 41 billion components and devices annually to drug developers worldwide.